Brutini 140 mg (Ibrutinib)

Description

[Indications] 1. Single drug is suitable for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. 2. Single drug is suitable for the treatment of patients with mantle cell lymphoma who have received at least one type of treatment in the past. 3. Single drug is suitable for the treatment of patients with Waldenstrom’s macroglobulinemia who have received at least one treatment in the past, or the first-line treatment of patients with Waldenström’s macroglobulinemia who are not suitable for chemical immunotherapy. 4. This product combined with rituximab is suitable for the treatment of patients with Waldenstrom’s macroglobulinemia.

【Dosage】 The recommended dose is 560 mg (4 140 mg capsules) taken orally once daily until disease progression or toxicity is intolerable. Swallow it with a glass of water at close to the same time each day. Do not open, break or chew the capsule.

【side effect】 Most common adverse reactions (≥20%) Diarrhea, bleeding (eg, bruising), fatigue, musculoskeletal pain, nausea, upper respiratory tract infection, cough, and rash Most common grade 3 or 4 adverse reactions (≥5%) Neutropenia, thrombocytopenia, infectious pneumonia, and anemia.

【Precautions】 1. Bleeding This product may increase the risk of bleeding in patients receiving antiplatelet or anticoagulant therapy, and patients should be monitored for signs of bleeding. 2. Infection For patients at increased risk for opportunistic infections, prophylaxis should be considered along with standard care. 3. Reduce blood cells Monitor complete blood counts monthly. 4. Interstitial lung disease Monitor patients for pulmonary symptoms suggestive of interstitial lung disease.

【Storage】 Store below 30℃.